AAAAAA
Results:
1-13
|
Results: 13
Authors:
Konecny, G
Untch, M
Arboleda, J
Wilson, C
Kahlert, S
Boettcher, B
Felber, M
Beryt, M
Lude, S
Hepp, H
Slamon, D
Pegram, M
Citation: G. Konecny et al., HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer, CLIN CANC R, 7(8), 2001, pp. 2448-2457
Authors:
Konecny, G
Untch, M
Pihan, A
Kimmig, R
Gropp, M
Stieber, P
Hepp, H
Slamon, D
Pegram, M
Citation: G. Konecny et al., Association of urokinase-type plasminogen activator and its inhibitor withdisease progression and prognosis in ovarian cancer, CLIN CANC R, 7(6), 2001, pp. 1743-1749
Authors:
Untch, M
Von Koch, F
Crohns, C
Sobotta, K
Kahlert, S
Konecny, G
Hepp, H
Citation: M. Untch et al., Dose-dense and sequential strategies in adjuvant breast cancer therapy, ONCOLOGY-NY, 15(5), 2001, pp. 14-20
Authors:
Konecny, G
Fritz, M
Untch, M
Lebeau, A
Felber, M
Lude, S
Beryt, M
Hepp, H
Slamon, D
Pegram, M
Citation: G. Konecny et al., HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer, BREAST CANC, 69(1), 2001, pp. 53-63
Authors:
Konecny, G
Untch, M
Slamon, D
Beryt, M
Kahlert, S
Felber, M
Langer, E
Lude, S
Hepp, H
Pegram, M
Citation: G. Konecny et al., Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples, BREAST CANC, 67(3), 2001, pp. 223-233
Authors:
Konecny, G
Frank, M
Kahlert, S
Untch, M
Hepp, H
Citation: G. Konecny et al., Retrospective analysis of dose intensity of epirubicin in breast cancer, GYNAKOL GEB, 40(3-4), 2000, pp. 145-152
Authors:
Konecny, G
Pegram, M
Slamon, D
Citation: G. Konecny et al., Docetaxel and trastuzumab: A combination with clinical relevance, ONKOLOGIE, 23, 2000, pp. 7-9
Authors:
Pegram, MD
Lopez, A
Konecny, G
Slamon, DJ
Citation: Md. Pegram et al., Trastuzumab and chemotherapeutics: Drug interactions and synergies, SEMIN ONCOL, 27(6), 2000, pp. 21-25
Authors:
Konecny, G
Crohns, C
Pegram, M
Felber, M
Lude, S
Kurbacher, C
Cree, IA
Hepp, H
Untch, M
Citation: G. Konecny et al., Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer, GYNECOL ONC, 77(2), 2000, pp. 258-263
Authors:
Konecny, G
Pegram, M
Untch, M
Thomssen, C
Janicke, F
Hepp, H
Slamon, DJ
Citation: G. Konecny et al., HER-2/neu as a predictive marker in breast cancer, GEBURTSH FR, 60(12), 2000, pp. 609-619
Authors:
Crohns, C
Konecny, G
Blokh, E
Kurbacher, C
Cree, I
Untch, M
Citation: C. Crohns et al., Is there a role for pretherapeutic chemosensitivity testing in breast cance?, GYNAKOLOGE, 32(9), 1999, pp. 705-709
Authors:
Kahlert, S
Untch, M
Konecny, G
Hepp, H
Citation: S. Kahlert et al., Cytostatic therapy for metastasized mammary carcinoma - New substances andinnovative combinations, GYNAKOLOGE, 32(8), 1999, pp. 614-623
Authors:
Konecny, G
Untch, M
Pegram, M
Citation: G. Konecny et al., Herceptin in the treatment of metastatic breast cancer, GYNAKOLOGE, 32(8), 1999, pp. 624-631
Risultati:
1-13
|